FDA Approvals for Liquid Epilepsy Drug and a Vitiligo Medication

In this episode, Ayesha discussed the FDA approval of Azurity Pharmaceutical’s Zonisade (zonisamide oral suspension) as an adjunct therapy for the treatment of seizures in adults and pediatric patients 16 years of age and older with epilepsy. The drug is the first FDA approved oral suspension form of zonisamide. Hear about how the drug could help increase accessibility and flexibility for epilepsy patients and improve treatment adherence. Ayesha also talked about biopharmaceutical company Incyte’s new vitiligo drug Opzelura that recently received FDA approval for the treatment of nonsegmental vitiligo. The topical medication is the first approved treatment for repigmentation in vitiligo and also the first approved topical JAK inhibitor in the US. Hear more about raising awareness about rare diseases like vitiligo and how it can help foster the development of new treatments.  Read the full articles here:  Zonisamide Liquid Form Gets FDA Approved for Epilepsy Treatment Opzelura Vitiligo Med Wins FDA Approval as First Treatment for Repigmentation For more life science and medical device content, visit the Xtalks Vitals homepage. Follow Us on Social Media Twitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured